Semaglutide (Novo Nordisk)

By analyzing over 400,000 Reddit posts, researchers discovered that users of popular GLP-1 weight-loss drugs frequently discussed unexpected symptoms like menstrual irregularities, chills, and hot flashes. The findings suggest AI could turn social media into a powerful early-warning system for spotting side effects that clinical trials may miss.Popular weight loss and diabetes medications such as semaglutide and tirzepatide have transformed treatment for obesity and blood sugar control. Now, researchers at the University of Pennsylvania say artificial intelligence may also help uncover side effects that patients are discussing online but that are not always fully reflected in clinical trials or official drug documentation. In a new study published in Nature Health, researchers analyzed more than 400,000 Reddit posts written by nearly 70,000 users over a span of more than five years. Their findings highlighted several commonly discussed symptoms, including some that may deserve closer scientific attention, such as menstrual irregularities and temperature-related complaints like chills and hot flashes. "Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal," says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study's senior author. "The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them." Lyle Ungar, Professor in CIS and a co-author of the study, says social media can offer insight into concerns patients may not always bring up during medical visits. "Clinical trials generally identify the most dangerous side effects of drugs," says Ungar. "But they can fail to find what symptoms patients are most concerned about; even though social media is not necessarily representative, a large collection of posts may reflect additional concerns." AI and Reddit Reveal Emerging GLP-1 Concerns The researchers emphasize that the study does not prove the medications caused the symptoms discussed online. Instead, the findings point to patterns that may warrant further investigation. "We can't say that GLP-1s are actually causing these symptoms," says Neil Sehgal, the study's first author and a doctoral student in CIS advised by Guntuku and Ungar. "But nearly 4% of the Reddit users in our sample reported menstrual irregularities, which would be even higher in a female-only sample. We think that's a signal worth investigating." The study builds on years of work examining online conversations for clues about drug side effects. Ungar participated in one of the earliest projects to mine user-generated internet content for reports of adverse drug reactions back in 2011. "Online patient communities work a lot like a neighborhood grapevine," says Ungar. "People who are living with these medications are swapping notes with each other in real time, sharing experiences that rarely make it into a doctor's office visit or an official report." As social media platforms have expanded, researchers say these discussions have become an increasingly valuable source of health-related information, even though collecting and analyzing the data has become more difficult over time. "Clinical trials are the gold standard, but by design, they are slow," says Guntuku. "This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight." Large Language Models Speed Up Side Effect Detection One major challenge in studying online health discussions has been scale. People describe symptoms in many different ways, making it difficult to systematically compare social media posts with standardized medical terminology from the Medical Dictionary for Regulatory Activities (MedDRA), which clinicians use to classify symptoms. The rise of large language models such as GPT and Gemini has changed that. According to the researchers, these AI systems now make it possible to process enormous amounts of online discussion much faster and with more consistency. "Large language models have made it possible to do this kind of analysis much faster with a level of standardization that could be difficult to achieve before," says Sehgal. Although Reddit users do not perfectly represent the general population because they tend to be younger, more likely to be male, and disproportionately based in the United States, many of the reported symptoms matched already known side effects of semaglutide and tirzepatide. About 44% of users in the study mentioned at least one side effect, most commonly gastrointestinal problems. Unexpected Symptoms Reported by GLP-1 Users What stood out to researchers were symptoms that may not be fully represented in current drug labeling or standard adverse event reporting systems. Nearly 4% of users who reported side effects also described reproductive symptoms, including irregular menstrual cycles, intermenstrual bleeding, and heavy bleeding. Other users reported temperature-related symptoms such as chills, feeling cold, hot flashes, and fever-like sensations. Fatigue also emerged as one of the most frequently discussed complaints. In fact, it ranked as the second most common symptom reported by Reddit users, despite appearing less prominently in many clinical trials. "These drugs are thought to work by engaging part of the brain called the hypothalamus, which helps regulate a wide variety of hormones," says Jena Shaw Tronieri, Senior Research Investigator at Penn's Center for Weight and Eating Disorders and a co-author of the study. "That doesn't mean the medications are necessarily causing these symptoms, but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically." Researchers Hope to Expand Beyond Reddit The team hopes the findings encourage scientists and healthcare providers to pay closer attention to the kinds of side effects patients are discussing online. "They're clearly on patients' minds, and that's worth paying attention to," says Sehgal. Researchers also plan to expand the analysis beyond Reddit and beyond English-speaking communities to determine whether similar patterns appear across other social media platforms and populations worldwide. "We don't really know yet whether what we're seeing on Reddit reflects the experience of GLP-1 users globally, or whether it's particular to the kind of person who posts on Reddit in the United States," says Ungar. Ultimately, the researchers believe AI-assisted analysis of social media conversations could become an important tool for identifying emerging concerns around medications and wellness trends much earlier than traditional systems allow. For rapidly spreading health products, especially substances sold in loosely regulated or unregulated markets such as injectable peptides, online conversations on platforms like Reddit and TikTok may provide some of the earliest clues about what users are experiencing. "The whole point of this kind of approach is that it can move quickly, and that's exactly when it's most valuable," says Guntuku. This study was conducted at the University of Pennsylvania School of Engineering and Applied Science. The authors report no outside funding. Tronieri reports receiving an investigator-initiated grant, on behalf of the University of Pennsylvania, from Novo Nordisk and receiving consulting fees from Currax Pharmaceuticals, LLC. The other authors report no conflicts of interest.

⚡ 每日新药情报简报（更新版） 2026年5月20日—5月23日 | 覆盖约72小时 生成时间：2026-05-23 19:30 CST | 补充：丁肝新药FDA批准 / 第一三共TNBC ADC获批 / EMA口服司美格鲁肽 🔄 本次更新（19:30）补充了三条遗漏的重要信息：①FDA加速批准吉利德Hepcludex（bulevirtide）治疗慢性丁肝（HDV）——首款FDA批准的丁肝疗法；②FDA批准第一三共/阿斯利康Datroway（datopotamab deruxtecan）一线治疗不适合免疫治疗的转移性TNBC；③EMA CHMP积极意见：诺和诺德Wegovy®口服片剂（25mg semaglutide）推荐批准用于体重管理，为欧盟首个口服GLP-1减肥疗法。 本期重点（更新版）： 🔥ASCO 2026倒计时6天——科伦博泰sac-TMT NSCLC一线III期PFS HR=0.35；中国生物制药M701恶性腹水III期；亚盛医药6项入选；CDE连发3项重磅指导原则 🦠FDA加速批准全球首款丁肝新药Hepcludex（bulevirtide），填补HDV治疗空白，基于MYR301 III期数据 🔥第一三共/阿斯利康Datroway获FDA批准一线治疗不适合免疫治疗的转移性TNBC，OS HR=0.79，为TROP2 ADC同类首个OS获益 🇪🇺EMA CHMP推荐批准诺和诺德Wegovy口服片剂（25mg semaglutide），欧盟首个口服GLP-1减肥疗法，减重16.6% 🏢丹诺医药港股上市——9,000倍超购，全球首创Hp新药+植入物感染药物双管线 NMPA国内审批动态 🔸 科伦博泰 芦康沙妥珠单抗+帕博利珠单抗 sNDA纳入优先审评 📅 2026.5.22-23公告 | 来源：科伦药业公告/上海证券报 基于OptiTROP-Lung05 III期研究（413例PD-L1 TPS≥1%初治晚期NSCLC），芦康沙妥珠单抗（sac-TMT, 4mg/kg Q2W）+帕博利珠单抗（400mg Q6W）对比帕博利珠单抗单药： 终点 联合组 单药组 HR/统计 mPFS (BICR)NR 5.7个月 HR=0.35, p<0.0001 ORR (BICR)70.2% 42.0% — OS（早期） HR=0.55 (95%CI 0.36-0.85) 数据未成熟 PD-L1 1-49%亚组 HR=0.28；PD-L1≥50%亚组 HR=0.47。ASCO口头报告 #8506（5/29 15:12）。 🔸 科伦博泰 仑博替尼 RET融合NSCLC关键II期 NDA获受理 📅 2026.5.22-23公告 | 来源：科伦药业公告 新一代选择性RET抑制剂，经治71例 IRC-ORR87.1%（mPFS 27.5月），初治92例 ORR81.3%。脑转移患者ORR分别为82.6%/75.0%。ASCO口头报告 #8505（5/29 14:36）。 🔸 中国生物制药 M701（CD3/EpCAM双抗）ASCO数据公布，上市申请已受理 📅 2026.5.22公告 | 来源：东方财富/格隆汇/公司公告 恶性腹水III期：mPuFS 87.59 vs 49.96天；mTTNP186.72vs 55.08天；2个月无穿刺率62.0% vs 38.4%。无严重CRS。2026年5月7日上市申请获CDE受理。 恶性胸水II期：mPuFS 130 vs 85天，计划启动III期。 🔸 丽珠集团 莱康奇塔单抗纳入CDE优先审评 📅 2026.5.21-22 | 来源：人民财讯/同花顺 1类创新药莱康奇塔单抗用于中重度斑块状银屑病适应症已纳入CDE优先审评，有望年内获批。 FDA美国FDA动态 🆕🔥 FDA加速批准 Hepcludex（bulevirtide）治疗慢性丁肝（HDV）——全球首款 📅 2026.5.22（今日）| 来源：吉利德公告/腾讯新闻/新浪财经/Investing.com 药物：Hepcludex®（bulevirtide注射液，8.5mg每日一次） 公司：吉利德科学（Gilead Sciences，2021年以约14.5亿欧元收购MYR GmbH获得） 机制：结合肝细胞表面NTCP受体，抑制HDV/HBV进入肝细胞及肝内扩散 审批路径：加速批准（Accelerated Approval），曾获突破性疗法认定、孤儿药资格、优先审评 适应症：无肝硬化或伴有代偿性肝硬化的成人慢性丁型肝炎病毒（HDV）感染 III期MYR301数据（第48周）： 终点 bulevirtide 8.5mg QD 延迟治疗组 联合应答率（HDV RNA↓≥2log+ALT正常）48% 2% HDV RNA不可检测率（第48周） 20% 0% HDV RNA不可检测率（第144周） 50% — HDV感染是最严重的病毒性肝炎，约1500万HBV/HDV合并感染者，可快速进展为肝癌/肝衰竭。此为FDA首次批准HDV疗法。 🆕🔥 FDA批准 Datroway（datopotamab deruxtecan）一线治疗不适合免疫治疗的转移性TNBC 📅 2026.5.22 | 来源：阿斯利康/第一三共联合公告/BusinessWire/AJMC/CureToday 药物：DATROWAY®（datopotamab deruxtecan-dlnk），靶向TROP2的DXd抗体偶联药物（ADC） 公司：第一三共发现，第一三共与阿斯利康共同开发及商业化 审批路径：优先审评（Priority Review） 适应症：不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌（TNBC）成人患者（一线治疗） III期TROPION-Breast02数据（vs 研究者选择化疗）： 终点 DATROWAY 化疗 HR/统计 中位OS ~23.7个月（约2年） 18.7个月 HR=0.79 (0.64–0.98), p=0.029 疾病进展/死亡风险 降低43% HR=0.57 (0.47–0.69), p<0.0001 ORR64% 30% — ✅首个且唯一在不适宜免疫治疗的一线转移性TNBC中证实OS显著获益的TROP2 ADC。已被NCCN指南列为Category 1首选一线方案。Project Orbis框架下同步在澳/加/新/瑞审评中。 ⏳ 5月末PDUFA日历 日期 药品 适应症 公司 5月29日 Afrezza（吸入胰岛素） 儿科糖尿病 MannKind 5月31日 CTx-1301（右哌甲酯） ADHD Cingulate 📊 2026年5月FDA累计批准新药（NDA/BLA新分子实体） 来源：FDA Novel Drug Approvals 2026 日期 药品 适应症 公司5.22Hepcludex (bulevirtide) 慢性丁肝(HDV) 吉利德5.22Datroway (datopotamab deruxtecan) TNBC一线（非PD-1/PD-L1候选） 第一三共/阿斯利康 5.18 Enhertu (T-DXd新适应症) HER2+乳腺癌等 第一三共/阿斯利康 5.15 Immgolis (新增规格/适应症) immunotherapy — 5.15 Baxfendy (baxdrostat) 高血压联合治疗 AstraZeneca 5.13 Beqalzi (sonrotoclax) R/R套细胞淋巴瘤 BeiGene 5.1 Veppanu (vepdegestrant) ER+/HER2- ESR1突变乳腺癌 Pfizer/Astrom EMA欧洲EMA动态 🆕🔥 EMA CHMP推荐批准诺和诺德Wegovy®口服片剂（25mg semaglutide）用于体重管理 📅 2026.5.22 | 来源：诺和诺德公告（公司公告第33/2026号）/GlobeNewswire/CRWE World 药品：Wegovy®pill（口服semaglutide片剂，25mg每日一次） 公司：诺和诺德（Novo Nordisk A/S） 决定：EMA人用药品委员会（CHMP）发布积极意见（positive opinion），推荐授予上市许可；最终批准由欧盟委员会作出 适应症：减少超重体重并维持长期体重减轻；标签将包含SELECT试验数据（降低MACE风险） IIIb期OASIS 4数据（64周，n=307）： 指标 口服semaglutide 25mg 安慰剂 平均体重减轻16.6% — 体重减轻≥20%的比例1/3受试者 — 疗效对比 与注射型Wegovy®2.4mg效果相当 ✅欧盟首个获CHMP推荐批准的口服GLP-1减肥疗法，代表同类最有效口服肥胖治疗药物。标签中无药物间相互作用限制。美国已批准，前4个月超100万美国人使用。欧盟预计2026年下半年上市。 CDE药品审评中心动态 📋 CDE发布《化学仿制药药学研究/BE研究重大缺陷情形》（2026年第36号） 📅 2026.5.20 | 来源：CDE官网/腾讯新闻/仪器信息网 药学研究新增3种重大缺陷： 起始原料选择不符合ICH Q11要求 审评期间变更需重新生产样品并重新考察稳定性 多亚批合并生产且无合理依据 BE研究新增3种重大缺陷： 代谢产物研究不支持评价 发生与研究药物相关的严重不良事件 达峰时间或吸收延迟时间存在临床意义的差异 适用于本通告发布之日起新受理品种，已受理品种按原审评尺度执行。 📋 CDE发布《M13A技术指导原则有关事项的说明》及第一批低风险制剂清单 📅 2026.5.20 | NMPA 2026年第49号公告 | 来源：CDE官网 国家药监局正式适用ICHM13A：口服固体速释制剂的生物等效性指导原则。CDE同步发布第一批低风险制剂清单，对低风险品种将动态更新。自发布之日起施行，中国BE研究标准全面对标国际ICH规范。 ASCO 2026倒计时6天——中国创新药强势集结 🔥 科伦博泰 芦康沙妥珠单抗：OptiTROP-Lung05 NSCLC一线III期 口头报告 #8506 ⏰ 5月29日 15:12-15:24 (芝加哥时间) | 来源：科伦药业公告/上海证券报 sac-TMT + Pembro vs Pembro单药，一线PD-L1 TPS≥1% NSCLC。PFSHR=0.35 (p<0.0001)，ORR 70.2% vs 42.0%，早期OS HR=0.55。sNDA已纳入NMPA优先审评。 🔥 科伦博泰 仑博替尼 RET融合NSCLC 口头报告 #8505 ⏰ 5月29日 14:36-14:48 | 来源：科伦药业公告 经治ORR87.1%，初治ORR81.3%，脑转移ORR 82.6%/75.0%。NDA已获受理。另：SKB500（B7-H3 ADC）I期快速口头报告#3011（6月2日）。 🔥 中国生物制药 M701 恶性腹水III期+恶性胸水II期 📅 2026.5.22公告 | 来源：东方财富/百家号 III期腹水：mPuFS 87.59 vs 49.96天，mTTNP186.72天（对照组55.08天），无严重CRS。国内首款CD3/EpCAM双抗。 🔥 亚盛医药 6项研究入选（3项快速口头+3项壁报） 📅 2026.5.22公告 | 来源：美通社/QQ新闻 涉及三大核心品种：奥雷巴替尼利沙托克拉alrizomadlin，覆盖CML、AML等血液/实体肿瘤。 📊 中国创新药ASCO 2026全景 来源：中信建投/东吴证券研报 指标 数据 中国研究入选总数94项 （连续三年创新高） Oral报告 34项 LBA入选 12家企业的13项（创历史新高） Plenary LBA 康方生物AK112 唯一入选中国项目 会期 5月29日—6月2日 芝加哥 临床其他临床进展 ✅ 礼来 Retatrutide TRIUMPH-1 III期 全部剂量组达终点 📅 2026.5.21 | 来源：新浪财经/163.com 平均减重28.3%（104周），最高剂量组达30.3%，为减重领域目前最高水平。 ✅ 科伦博泰 芦康沙妥珠单抗 三线开花（TNBC+子宫内膜癌+NSCLC） 📅 2026.5.21 | 来源：科伦博泰公告 TNBC一线III期(OptiTROP-Breast03)达PFS主要终点——首个国产TROP2 ADC一线TNBC阳性结果；子宫内膜癌III期(TroFuse-005)达OS+PFS双主要终点。 ✅ Regeneron Lynozyfic AL淀粉样变性I/II期积极 📅 2026.5.22 | 来源：RTTNews LINKER-AL2试验在复发/难治性系统性轻链淀粉样变性中显示令人鼓舞的疗效。 ✅ OSE Tedopi±Keytruda 卵巢癌II期(TEDOVA)达到积极顶线 📅 2026.5.22 | 来源：RTTNews 铂敏感复发性卵巢癌维持治疗II期试验达到积极顶线结果。 ❌ Biogen/Denali BIIB122 帕金森病IIb期(LUMA, 648例)失败终止 📅 2026.5.22 | 来源：FierceBiotech/BioSpace 未达到主要/次要终点，双方决定终止开发。 ✅ Bayer Kerendia（非奈利酮）sNDA获FDA优先审评 📅 2026.5.21 | 来源：拜耳官网/医药魔方 1型糖尿病合并CKD新适应症，基于FINE-ONE III期研究。PDUFA预计2026年Q4。 BD交易与企业动态 🏢 丹诺医药（6872.HK）港交所上市 首日涨超99% 📅 2026.5.22 | 来源：新浪财经/乐居财经/百家号 发行价75.70港元，募资约6.27亿港元，香港公开发售获9,015倍认购。两大全球首创产品：利福特尼唑（TNP-2198） ：全球首个幽门螺杆菌新分子实体，III期根除率>90%，NDA已受理（预计2026年底获批）利福喹酮（TNP-2092） ：全球首个植入物感染药物，美国II期临床反应率76.9%，FDA快速通道+QIDP认定 开业首日涨幅99.5%，收盘市值约78亿港元。 🏢 南京医药 拟4.5亿设并购基金收购大清生物+科健科技 📅 2026.5.21 | 来源：南京医药公告/每日经济新闻 南京医药（600713）拟出资不超过4.5亿元，并购大清生物44.95%股权（约3.4亿元）及科健科技50.98%股权（约4.08亿元）。 📌 本期信息优先级索引（更新版） 优先级 动态 日期 状态 ① FDA🆕 Hepcludex（bulevirtide）加速批准—全球首款丁肝新药 5.22 ✅ 加速批准 ① FDA🆕 Datroway（datopotamab deruxtecan）TNBC一线获批 5.22 ✅ 优先审评批准 ① EMA🆕 Wegovy口服片剂CHMP积极意见—欧盟首个口服GLP-1减肥药 5.22 ⏳ CHMP推荐 ① NMPA 科伦博泰 sac-TMT+Pembro sNDA优先审评 5.22-23 ✅ 受理 ① NMPA 科伦博泰 仑博替尼 NDA受理 5.22-23 ✅ 受理 ① NMPA 丽珠 莱康奇塔单抗 优先审评 5.21-22 ✅ 优先审评 ② FDA 5月末PDUFA：Afrezza (5.29) + CTx-1301 (5.31) 5.29/31 ⏳ 待审 ② FDA Bayer Kerendia sNDA优先审评（T1D+CKD） 5.21 ⏳ 优先审评 ③ CDE 仿制药药学研究/BE重大缺陷情形（2026第36号） 5.20 ✅ 发布生效 ③ CDE M13A BE指导原则+第一批低风险制剂清单 5.20 ✅ 发布生效 ④ ASCO 科伦博泰 sac-TMT NSCLC Oral #8506 + 仑博替尼 Oral #8505 5.29 🔥 ASCO Oral ④ ASCO 中国生物制药 M701 III期数据公布 5.22 🔥 ASCO ④ ASCO 亚盛医药 6项ASCO入选（3快速口头+3壁报） 5.22 🔥 ASCO ④ 临床 礼来 Retatrutide减重28.3% 5.21 ✅ III期阳性 ④ 临床 Regeneron Lynozyfic AL淀粉样变性 5.22 ✅ I/II期积极 ④ 临床 Biogen/Denali BIIB122 PD失败 5.22 ❌ 终止 ⑤ BD 丹诺医药港股IPO 9000倍超购 5.22 ✅ 上市 ⑤ BD 南京医药4.5亿并购大清生物+科健 5.21 ✅ 公告 ⑥ 指导 CDE 3项重磅指导原则同日发布 5.20 ✅ 生效 ⚙️ 搜索策略优化记录（本次更新） 本次发现的三条遗漏信息的搜索盲区： 丁肝 HDVHepcludex bulevirtide吉利德 Gilead Datrowaydatopotamab deruxtecanTNBC 一线第一三共 Daiichi Sankyo EMA CHMPoral semaglutideWegovy pill口服司美格鲁肽 优化措施（已更新至搜索策略）：FDA批准搜索 ：增加"accelerated approval"+"today"+"yesterday"时间限定词；增加具体疾病名（HDV、丁肝、TNBC）作为独立搜索条目ADC/TROP2类药物 ：将Datroway、sacituzumab、datopotamab deruxtecan列入FDA批准监测关键词表EMA CHMP动态 ：新增EMA CHMP积极意见（positive opinion）作为独立搜索模块，覆盖"CHMP positive opinion"+"recommended for approval"+具体日期口服GLP-1 ：将"oral semaglutide"、"Wegovy pill"、"Rybelsus"、"口服司美格鲁肽"列入EMA/FDA双轨监测稀有疾病新药 ：增加HDV、丁肝、AL淀粉样变性、恶性腹水等罕见适应症的专用搜索关键词，避免仅依赖公司名搜索导致遗漏 本简报由 AI 自动化生成，信息来源包括 NMPA/CDE/FDA/EMA 官网、医药魔方、丁香园、新浪财经、腾讯新闻、RTTNews、FierceBiotech、BusinessWire、GlobeNewswire 等 部分信息为公开报道整合，具体数据以官方公告为准 | 每日19:00自动采集 | 更新版 2026-05-23 19:30